Roche closes the acquisition of a Chinese obesity drug for 1.037 billion - El Español
Article excerpt
Highlighted: the sentence this signal was extracted from
Roche logo. - Roche agrees to buy an interfering RNA obesity drug from China's Rona Therapeutics for up to 1.160 billion dollars. The Swiss pharmaceutical company will pay an initial 100 million dollars and the rest conditioned on milestones and global sales royalties. The move seeks to compete in the weight loss treatment market, currently led by pharmaceutical companies Lilly and Novo Nordisk. Roche is also advancing with 'enicepatide', its other candidate drug against obesity and diabetes which plans new clinical trials in 2027. More moves in the obesity market. Roche has announced the acquisition of a weight loss drug for 1.160 billion dollars (1.037 billion euros). The agreement has been closed with China's Rona Therapeutics, a biotechnology company that develops medicines through interfering RNA technology. With this agreement, the Chinese company will receive an initial payment of 100 million dollars and could receive up to 1.060 billion dollars in potential milestone payments, as well as tiered royalties on global net sales. The investigational interfering RNA (RNAi) drug candidate is aimed at treating obesity and metabolic diseases. In this way, Roche is competing to enter the weight-loss drug market, dominated by Lilly and Novo Nordisk. Exactly a year ago, the Swiss company announced the manufacturing of its obesity drug in collaboration with Rovi. The Madrid-based...
Keep reading with a free account
The rest of this article, and every signal for Roche, is in your free account.
